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Abstract Hemorrhagic transformation is a major complication associated with 
tissue plasminogen activator (tPA) therapy for ischemic stroke. We studied the effect of 
tPA on the blood-brain barrier (BBB) function with our in vitro monolayer model 
generated using rat brain microvascular endothelial cells subjected either to normoxia, 
or to hypoxia/reoxygenation with or without the administration of tPA. The barrier 
function was evaluated by the transendothelial electrical resistance, the permeability of 
sodium fluorescein and Evans’ blue-albumin, and the uptake of lucifer yellow. The 
permeability of sodium fluorescein and Evans’ blue-albumin was used as an index of 
paracellular and transcellular transport, respectively. The administration of tPA 
increased the permeability of Evans’ blue-albumin and the uptake of lucifer yellow 
under normoxia. It enhanced the increase in the permeability of both sodium fluorescein 
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and Evans’ blue-albumin, the decrease of the transendothelial electrical resistance, and 
the disruption in the expression of ZO-1 under hypoxia/reoxygenation conditions.  
Administration of tPA could cause an increase in the transcellular transport 
under normoxia, and both the transcellular and paracellular transport of the BBB under 
hypoxia/reoxygenation conditions in vitro. Even in humans, tPA may lead to an opening 
of the BBB under non-ischemic conditions, and have an additional effect on the 
ischemia-induced BBB disruption.  
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Tissue plasminogen activator (tPA) is a serine protease that activates plasminogen into 
plasmin, leading to the degradation of fibrin clots (Vassalli et al., 1991). Thrombolytic 
therapy with tPA is widely accepted to be effective for the treatment of acute 
thromboembolic stroke (NINDS, 1995), however, symptomatic brain hemorrhaging 
remains a major complication associated with such a treatment (NINDS, 1997). 
Moreover, tPA has been reported to potentiate neuronal death both in vitro and in vivo 
(Liu et al., 2004). Therefore, it is considered very important to investigate the effect of 
tPA on the blood-brain barrier (BBB) function. Recently, it has been suggested that tPA 
promotes leakage of the BBB (Yepes et al., 2003), which is in agreement with the ability 
of tPA to generate hemorrhage (NINDS, 1997). In contrast, other in vivo studies have 
shown that tPA injection does not compromise the BBB integrity in the acute stage of 
cerebral ischemia (Benchenane et al., 2005). 
The major aim of the present study was to investigate the effect of tPA on BBB function. 
First, we established a pathophysiological in vitro BBB model by exposing the 
endothelial cells to normoxic or hypoxia/reoxygenation (H/R) conditions. Second, we 
investigated the effect of tPA on the transcellular and paracellular transport using the 
same BBB model subjected to H/R conditions.  
 
Materials and Methods 
 
All reagents were purchased from Sigma, USA, unless otherwise indicated. Wistar rats 
were obtained from Japan SLC Inc., Japan. All animals were treated in strict accordance 
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with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publications No. 80-23) and as approved by the Nagasaki University 
Animal Care Committee. Human recombinant tPA (Alteplase) was provided by Kyowa 




Primary cultures of rat brain capillary endothelial cells (RBEC) were prepared from 
3-week-old rats, as previously described (Deli et al., 1997; Hayashi et al., 2004). The 
meninges were carefully removed from the forebrains and the gray matter was minced 
into small pieces of approximately 1 mm3 in ice-cold Dulbecco’s modified Eagle’s 
medium (DMEM), then dissociated by 25 up- and down-strokes with a 5-ml pipette in 
DMEM containing collagenase type 2 (1 mg/ml, Worthington, USA), 300 μl DNase 
(15 μg/ml), gentamicin (50 μg/ml), and then were digested in a shaker for 1.5 h at 37°C. 
The cell pellet was separated by centrifugation in 20% bovine serum albumin 
(BSA)-DMEM (1000g, 20 min). The microvessels obtained in the pellet were further 
digested with collagenase-dispase (1 mg/ml, Roche, Switzerland) and DNase 
(6.7 μg/ml) in DMEM for 0.5 h at 37°C. Microvessel endothelial cell clusters were then 
separated on a 33% continuous Percoll (Pharmacia, Sweden) gradient, collected and 
washed twice in DMEM before plating on 35-mm plastic dishes coated with collagen 
type IV and fibronectin (both 0.1 mg/ml). The RBEC cultures were maintained in 
DMEM/Nutrient Mixture F-12 Ham (DMEM/F12) supplemented with 10% plasma 
derived serum (PDS, Animal Technologies, USA), basic fibroblast growth factor (bFGF, 
Roche, Switzerland, 1.5 ng/ml), heparin (100 μg/ml), insulin (5 μg/ml), transferrin 
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(5 μg/ml), sodium selenite (5 ng/ml) (insulin-transferrin-sodium selenite media 
supplement), gentamicin (50 μg/ml), and puromycin (4 μg/ml) (Perriere et al., 2005) 
(RBEC medium I) at 37°C with a humidified atmosphere of 5% CO2/95% air, for 2 days. 
On the third day, the cells received a new medium which contained all the components 
of RBEC medium I except puromycin (RBEC medium II).  
 
BBB in vitro monolayer model  
 
When the cultures reached 80% confluency (fourth day in vitro), the purified endothelial 
cells were passaged by a brief treatment with trypsin (0.05% wt/vol)-EDTA (0.02% 
wt/vol) solution. The endothelial cells (2.0×105 cells/cm2) were seeded on the upper side 
of the polyester membrane of Transwell○R  inserts (diameter 12 mm, 0.40 μm pore size; 
Corning, Midland, MI) coated with collagen type IV and fibronectin. The day when the 
endothelial cells were plated was defined as Day 0 in vitro. From Day 1, the culture 
medium was supplemented with 500 nM hydrocortisone (Hoheisel et al., 1998). On Day 
5, the experiments were performed. All experiments were repeated at least 3 times, and 
the number of parallel inserts was 4. 
 
Hypoxia/reoxygenation Studies  
 
Normoxia: The cells were transferred to a serum-free medium containing 4.5 g/L 
glucose (control medium), DMEM/F12, with or without administration of tPA (20 
μg/ml). We used a dose of 20 µg/mL of tPA, based on the observation that such a 
 6
concentration can be reached in blood (Godfrey et al., 1998). tPA was added in the 
luminal face at different 3 incubation times (3 h, 6 h, 9 h).  
Hypoxia/reoxygenation conditions: H/R conditions consisted of 6 h hypoxia 
and 3 h reoxygenation with or without the administration of tPA. Hypoxia was 
generated using the AnaeroPack (Mitsubishi Gas Chemical). Briefly, cells were 
transferred to a serum- and glucose-free medium, Krebs-Ringer buffer (117 mM NaCl, 
4.7 mM KCl, 1.2 mM Mg Cl2, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.5mM CaCl2, PH 
7.4), which was previously bubbled with nitrogen gas for 30 min. Reoxygenation was 
initiated by adding serum-free medium, DMEM/F12. In all experiments, the pH of the 
medium remained stable during H/R conditions.  
 
Transendothelial Electrical Resistance (TEER) 
 
The electrical resistance across the membrane was measured using an EVOM resistance 
meter (World Precision Instruments, Sarasota, FL). The extracellular matrix-treated 
Transwell○R  inserts were placed in a 12-well plate containing culture medium and then 
were used to measure the background resistance. The resistance measurements of these 
blank filters were then subtracted from those of filters with cells. The values are shown 




The flux of sodium fluorescein (Na-F) and Evan's blue-albumin (EBA) across the 
endothelial monolayer was determined as previously described (Kis et al., 2001). Cell 
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culture inserts were transferred to 12-well plates containing 1.5 ml assay buffer 
(136 mM NaCl, 0.9 mM CaCl2, 0.5 mM MgCl2, 2.7 mM KCl, 1.5 mM KH2PO4, 10 mM 
NaH2PO4, 25 mM glucose, and 10 mM Hepes, pH 7.4) in the basolateral or lower 
compartments. In the inserts, the culture medium was replaced by 0.5 ml buffer 
containing 10 μg/ml Na-F (MW: 376 Da) and 165 μg/mL Evans’ blue bound to 0.1% 
BSA (mw: 67 kDa). The inserts were transferred at 15, 30, and 60 min to a new well 
containing assay buffer. The emission of Na-F was measured at 535 nm (Wallac 1420 
ARVO Multilabel Counter, Perkin Elmer; excitation: 485 nm), while the absorbency of 
Evans’ blue is at 595 nm. The permeability of Na-F and EBA was used as an index of 
paracellular and transcellular transport, respectively.  The apparent permeability 
coefficient , namely Papp (cm/s), derives from Fick’ s Law (Youdim et al., 2003). 
 
Assessment of Cell Viability 
 
The endothelial cells (2.5×104 cells/cm2) were seeded on the bottom side of a 24-well 
plate coated with collagen type IV and fibronectin. On Day 5, the experiments were 
performed. The effect of tPA on the viability of the endothelial cells was assessed using 
a Vi-CELLTM Cell Viability Analyzer (Beckman Coulter, Inc., Miami, FL). Viable 
cells were counted by trypan blue exclusion. The relative viable cell density 






The endothelial cells (2.5×104 cells/cm2) were seeded on the bottom side of a 24-well 
plate coated with collagen type IV and fibronectin. On Day 5, the experiments were 
performed. The uptake of lucifer yellow (LY) by the RBECs was determined by the 
methods described elsewhere with a slight modification of the technique (Niwa et al., 
2004). We chose the concentration of LY to be 100 μg/ml. After incubation of the cells 
for 2 h, the cells were washed 4 times with cold PBS and lysed with 2 ml of 0.2% Triton 
X-100 in PBS. The cell lysates were centrifuged to remove cell debris, and the 
fluorescence intensity of the supernatant was then measured (Wallac 1420 ARVO 




The cells were fixed in 3% paraformaldehyde in phosphate-buffered saline (PBS) for 
10 min, as previously described (Honda et al., 2006). Nonspecific reactions were 
blocked by 3% BSA in PBS for 30min and then the cells were incubated with primary 
antibody (ZO-1; Zymed, San Francisco, CA) overnight at 4°C. The cells were rinsed 
with PBS and incubated for 1 h at room temperature with the appropriate secondary 
antibodies labeled with Alexa Fluor 488 (green) (Molecular Probes, Eugene, OR). All 
samples were examined using a laser-scanning confocal microscope (LSM 5 PASCAL, 
Carl Zeiss) with excitation at 488 nm and a detection range from 500 to 535 nm.  
 
Statistical Analysis 
Data were all expressed as the mean±standard deviation (SD). The effects of tPA on the 
permeability of Na-F, EBA, the cell viability, the uptake of LY and the TEER were 
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analyzed by ANOVA (analysis of variance) for the two-way layout data; the linear 
models including the terms of two main factors and their interaction were used, and if 
any factors or interactions were found to be significant, then the respective two groups 
were compared by t tests with the Bonferroni adjustment. We used TTEST and ANOVA 
of SAS○R  system for the calculations. We considered a p-value of less than 0.05 to 




The TEER of this monolayer model displayed more than 100 Ω×cm2. With respect to 
the permeability of Na-F and EBA under normoxia, no significant difference according 
to the incubation time was observed in controls (Fig. 1 A and B). The administration of 
tPA (20 µg/mL, incubation at 37°C) had no effect on the permeability of Na-F, while it 
showed a significant effect on the permeability of EBA (0.23±0.04 vs 0.40±0.07 ×10-6 
cm/s at 3h, 0.20±0.04 vs 0.53±0.05 ×10-6 cm/s at 6h and 0.23±0.06 vs 0.48±0.09 ×10-6 
cm/s at 9h; p < 0.0001) (Fig. 1 A and B).  
No effect of the tPA administration was observed at different 3 incubation times 
(3 h, 6 h, 9 h) in regard to the cell viability (Fig. 2). The administration of tPA increased 
the uptake of LY under normoxia, and the effect was significant at an incubation time of 
6 h (0.49±0.16 vs 1.13±0.67 μg/mg protein; p =0.0074) and 9 h (0.37±0.26 vs 
1.09±0.50; p = 0.0004) (Fig. 3).  
Since the two-way ANOVA demonstrated a significant effect of interaction 
between conditions (normoxia and H/R conditions) and treatments (vehicle and tPA 
administration) (F = 31.4 and 24.9 for Na-F and EBA permeability, respectively; p < 
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0.0001 for both) as well as the significant effects of conditions (F = 285.3 and 94.9 for 
Na-F and EBA, respectively; p < 0.0001 for both) and treatments (F = 36.3 and 242.8 
for Na-F and EBA, respectively; p < 0.0001 for both), we analyzed the effects of tPA 
under normoxia and H/R conditions separately. Under normoxia (incubation time; 9h), 
the administration of tPA had no significant effect on the permeability of Na-F, while it 
significantly increased the permeability of EBA (0.23±0.06 vs 0.48±0.09 ×10-6 cm/s; p 
< 0.0001) (Fig. 4 A and B). On the other hand, under H/R conditions, the administration 
of tPA significantly increased the permeability of Na-F (5.70±0.75 vs 9.32±0.95 ×10-6 
cm/s; p < 0.0001) and EBA (0.34±0.09 vs 0.84±0.09 ×10-6 cm/s; p < 0.0001) (Fig. 4 A 
and B).  
Furthermore, the permeability of Na-F was also significantly higher under H/R 
conditions than under normoxia both with (4.24±0.69 vs 9.32±0.95 ×10-6 cm/s; p < 
0.0001) and without (4.15±0.70 vs 6.70±0.75 ×10-6 cm/s; p < 0.0001) the administration 
of tPA; similar results held for the permeability of EBA with (0.48±0.09 vs 0.84±0.09 
×10-6 cm/s; p = 0.0013) and without (0.23±0.06 vs 0.34±0.09 ×10-6 cm/s; p < 0.0001) 
the administration of tPA, respectively (Fig. 4 A and B).  
A similar separate analysis was carried out for TEER since the interaction 
between conditions and treatments was significant (F = 9.7, p < 0.0033) as well as the 
effects among such conditions (F = 814.5, p < 0.0001) or treatments (F = 20.2, p < 
0.0001). The TEER was significantly lower under H/R conditions than normoxia for 
both with (22.00±3.33 vs 105.92±6.79 Ω×cm2; p < 0.0001) and without (42.17±3.43 vs 
109.58±16.38 Ω×cm2; p < 0.0001) the administration of tPA. The administration of tPA 
significantly decreased the TEER under H/R conditions (42.17±3.43 vs 22.00±3.33 
Ω×cm2; p < 0.0001) (Fig. 5).  
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H/R decreased the expression of ZO-1. Moreover, tPA enhanced the disruption 




In the present study, we established a pathophysiological in vitro BBB model by 
exposing the endothelial cells to normoxia or H/R. Other in vitro studies have 
demonstrated that hypoxia with reoxygenation increases endothelial cell permeability 
(Utepbergenov et al., 1998; Dohgu et al., 2007; Nishioku et al., 2007). In this study, the 
exposure times to hypoxia and reoxygenation were determined as 6 h and 3 h, 
respectively, to cause dysfunction of the endothelial cells. The results showed that H/R 
conditions led to an increase in the permeability of both Na-F and EBA, and a decrease 
of the TEER. Moreover, H/R conditions reduced the expression of ZO-1. These findings 
indicate that H/R induced paracellular hyperpermeability mediated by changes of TJ 
expression, and transcellular hyperpermeability. The exposure of brain-derived 
endothelial cells to hypoxic conditions has been reported to cause alterations in occludin, 
ZO-1, ZO-2, and claudin-5 localization (Mark et al., 2002; Fischer et al., 2004; Koto et 
al., 2007). 
 Regarding the next concern, we demonstrated that in this in vitro 
monolayer model, tPA at a concentration of 20 μg/ml induced an increase in the 
permeability of EBA and an uptake of LY during normoxia, which suggested that tPA 
may increase the transcellular transport. These results seem to correlate with Yepes’ in 
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vivo observations that tPA led to an opening of the BBB by a mechanism involving 
low-density lipoprotein receptor-related protein in the absence of brain injury (Yepes et 
al., 2003). Deli et al. reported that tPA dose-dependently inhibited P-glycoprotein 
activity during normoxia (Deli et al., 2001). Benchenane et al. reported that oxygen and 
glucose deprivation (4 h) enhances an increase in the permeability of both sucrose and 
inulin (Benchenane et al., 2005). We showed that the co-application of tPA exacerbated 
the increase in the permeability of both Na-F and EBA. In addition, tPA enhanced the 
decrease of the TEER and the disruption in the expression of ZO-1 during this H/R 
conditions in our study. Our recent study reported that cellular communications play an 
important role in inducing and maintaining the barrier function of brain endothelial cells 
(Nakagawa et al., 2007). Cheng et al. showed that tPA induced NF-κΒ-dependent 
upregulation of metalloproteinase-9 in ischemic brain endothelium in vivo and in vitro 
(Cheng et al., 2006). Wang et al. that reported tPA induced metalloproteinase-9 
dysregulation in rat cortical astrocytes (Wang et al., 2006). These results require further 
study using the in vitro co-culture model to assess the effect of tPA on the BBB. These 
findings raise the possibility that in humans, preventing the tPA-induced 
hyperpermeability of the BBB may be an adjunctive strategy to diminish the potentially 
deleterious effects of tPA.  
 In summary, tPA could therefore cause an increase in the transcellular 
transport under normoxia, and both the transcellular and paracellular transport of the 
BBB under H/R conditions in vitro. In humans, tPA may thus lead to an opening of the 
BBB under non-ischemic conditions, thereby having an additional effect on the 
ischemia-induced BBB disruption.  
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Fig. 1  Under normoxia, the administration of tPA had no effect on the permeability of 
sodium fluorescein (Na-F) (A), while it showed a significant effect on the permeability 





Fig. 2  No effect of the tPA administration was observed at different 3 incubation times 
(3 h, 6 h, 9 h) in regard to the cell viability under normoxia. The values are the 




Fig. 3  The administration of tPA increased the uptake of lucifer yellow (LY) under 
normoxia, and the effects were significant after an incubation time of 6 h and 9 h. The 




Fig. 4  A; Under H/R conditions, the administration of tPA significantly increased the 
permeability of sodium fluorescein (Na-F), and the permeability of Na-F was 
significantly higher under H/R conditions than under normoxia both with and without 
the administration of tPA. B; Under normoxia (incubation time; 9h), the administration 
of tPA significantly increased the permeability of Evans’ blue-albumin (EBA). 
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Moreover, under H/R conditions, the administration of tPA significantly increased the 
permeability of EBA. The permeability of EBA was significantly higher under H/R 
conditions than under normoxia both with and without the administration of tPA. The 
values are the mean±SD, n=12. Significant differences between the normoxia and H/R 
are indicated as *p<0.05. Significant differences between the control and tPA 




Fig. 5  The transendothelial electrical resistance (TEER) was significantly lower under 
H/R conditions than under normoxia both with and without the administration of tPA. 
The administration of tPA significantly decreased the TEER under H/R conditions. The 
values are the mean±SD, n=12. Significant differences between normoxia and H/R are 
indicated as *p<0.05. Significant differences between the control and tPA administration 




Fig. 6  The ZO-1 protein expression was analyzed immunocytochemically using 
anti-ZO-1 antibody. Under normoxia (incubation time; 9h), the administration of tPA 
showed no effects on the expression of ZO-1 (A and B). H/R decreased the expression 
of ZO-1 (C), and administration of tPA enhanced the disruption in the expression of 
ZO-1 during H/R conditions (D). 
 
